Paying membership fees with pretax employer dollars held cost growth to 0.9% a year, but the numbers come with caveats physicians should know before pitching employers.
Prior authorization, step therapy and shifting coverage rules keep patients from obesity drugs with proven benefits, an endocrinologist argues — and the long-term savings make the case for broader access.